β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis
The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.
Abstract
PURPOSE: Congestive heart failure is an important cause of patient morbidity and mortality. Although several randomized clinical trials have compared beta-blockers with placebo for treatment of congestive heart failure, a meta-analysis quantifying the effect on mortality and morbidity has not been performed recently. DATA SOURCES: The MEDLINE, Cochrane, and Web of Science electronic databases were searched from 1966 to July 2000. References were also identified from bibliographies of pertinent articles. STUDY SELECTION: All randomized clinical trials of beta-blockers versus placebo in chronic stable congestive heart failure were included. DATA EXTRACTION: A specified protocol was followed to extract data on patient characteristics, beta-blocker used, overall mortality, hospitalizations for congestive heart failure, and study quality. DATA SYNTHESIS: A hierarchical random-effects model was used to synthesize the results. A total of 22 trials involving 10 135 patients were identified. There were 624 deaths among 4862 patients randomly assigned to placebo and 444 deaths among 5273 patients assigned to beta-blocker therapy. In these groups, 754 and 540 patients, respectively, required hospitalization for congestive heart failure. The probability that beta-blocker therapy reduced total mortality and hospitalizations for congestive heart failure was almost 100%. The best estimates of these advantages are 3.8 lives saved and 4 fewer hospitalizations per 100 patients treated in the first year after therapy. The probability that these benefits are clinically significant (>2 lives saved or >2 fewer hospitalizations per 100 patients treated) is 99%. Both selective and nonselective agents produced these salutary effects. The results are robust to any reasonable publication bias. CONCLUSIONS: beta-Blocker therapy is associated with clinically meaningful reductions in mortality and morbidity in patients with stable congestive heart failure and should be routinely offered to all patients similar to those included in trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a meta-analysis of more than 10,000 patients, β-blockers prevented 3.8 deaths and were associated with 4 fewer hospitalizations per 100 patients in the first year of treatment.28”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [28]
In the citing paper
“In those post-myocardial infarction and in heart failure patients, use of beta-blockade in carefully titrated doses is associated with improved outcomes.62,63”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [63]
Citations
Cites
Gelman, A., Carlin, J. B., Stern, H. S., & Rubin, D. B. (2003) · doi:10.1201/9780429258480 · Cited by 27,276
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Swedberg, K., & Kjekshus, J. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
The effect of digoxin on mortality and morbidity in patients with heart failure
(1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360801 · Cited by 3,016
Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
Packer, M., Carver, J. R., Rodeheffer, R. J., Ivanhoe, R. J., DiBianco, R., Zeldis, S. M., Hendrix, G. H., Bommer, W. J., Elkayam, U., Kukin, M. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252103 · Cited by 2,225
Garg, R. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520420066040 · Cited by 1,771
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Waldo, A. L., Camm, A. J., deRuyter, H., Friedman, P. L., MacNeil, D. J., Pauls, J. F., Pitt, B., Pratt, C. M., Schwartz, P. J., & Veltri, E. P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)02149-6 · Cited by 1,371
Research works printed but not linked: 3
- Brophy JM, 1992, Can J Cardiol, 8, 495
- Packer M, 1993, Circulation, 88
- Avezum A, 1998, Can J Cardiol, 14, 1045
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
“For example, of the 22 trials addressing the impact of beta-blockers onmortality in patientswith heart failure, most, probably or certainly, used concealed allocation, all blinded at least some key groups, and follow up of randomized patients was almost complete [26].”
Background
Metadata
- Authors
- Brophy, J. M., Joseph, L., & Rouleau, J. L.
- Affiliations
- Mount Sinai Hospital (CA)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2001-04-03
- Volume
- 134
- Issue
- 7
- Pages
- 550-560
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2023629207
- Cited by
- 389
- References
- 57
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 9 · 2020: 5 · 2019: 11 · 2018: 9 · 2017: 15 · 2016: 17 · 2015: 14 · 2014: 10 · 2013: 21 · 2012: 26
- FWCI
- 18.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- beta-blockers, congestive heart failure, mortality, hospitalization, selective beta-blockers, non-selective beta-blockers, treatment efficacy, publication bias
- MeSH terms
- Adrenergic beta-Antagonists, Bayes Theorem, Heart Failure, Hospitalization, Humans, Research Design, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis. https://app.cochat.ai/papers/10.7326/0003-4819-134-7-200104030-00008
- The paper
- Brophy, J. M., Joseph, L., & Rouleau, J. L. (2001). β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-134-7-200104030-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.